Life SciencesNeurosciencePharmacologyMolecular NeurobiologyMolecular NeuroscienceNeurodegenerationAlzheimer DiseaseMolecular Basis Of NeurodegenerationNeurodegeneration MechanismsNeurodegenerative DiseasesNeurodegenerative DisordersNeuroprotectionAlzheimer Disease DementiaAlzheimer Disease NeuroprotectionAmyloid Beta PeptidesAmyloid Beta PlaquesPeroxisome Proliferator-activated Receptor SignalingPeroxisome Proliferator-activated ReceptorsReal-time Polymerase Chain Reaction (Pcr)Western Blotting
BACKGROUND AND PURPOSE: The present study was designed to examine the effects of ginsenoside Rg1 on expression of peroxisome proliferator-activated receptor γ (PPARγ) and insulin-degrading enzyme (IDE) in the hippocampus of rat model of Alzheimer's disease (AD) to determine how ginsenoside Rg1 (Rg1) decreases Aβ levels in AD. EXPERIMENTAL APPROACH: Experimental AD was induced in rats by a bilateral injection of 10 µg soluble beta-amyloid peptide 1-42 (Aβ(1-42)) into the CA1 region of the hippocampus, and the rats were treated with Rg1 (10 mg·kg(-1), intraperitoneally) for 28 days. The Morris water maze was used to test spatial learning and memory performance. Hematoxylin-eosin staining was performed to analyze the hippocampal histopathological damage. Immunohistochemistry, western blotting, and real-time PCR were used to detect Aβ(1-42), PPARγ, and insulin-degrading enzyme (IDE) expression in the hippocampus. KEY RESULTS: Injection of soluble Aβ(1-42) into the hippocampus led to significant dysfunction of learning and memory, hippocampal histopathological abnormalities and increased Aβ(1-42) levels in the hippocampus. Rg1 treatment significantly improved learning and memory function, attenuated hippocampal histopathological abnormalities, reduced Aβ(1-42) levels and increased PPARγ and IDE expression in the hippocampus; these effects of Rg1 could be effectively inhibited by GW9662, a PPARγ antagonist. CONCLUSIONS AND IMPLICATIONS: Given that PPARγ can upregulate IDE expression and IDE can degrade Aβ(1-42), these results indicate that Rg1 can increase IDE expression in the hippocampus by upregulating PPARγ, leading to decreased Aβ levels, attenuated hippocampal histopathological abnormalities and improved learning and memory in a rat model of AD.
42
Wesley Farris, Stefan Mansourian, Yang Chang et al. · Proceedings of the National Academy of Sciences · 2003 · 1.5K citations · Full text
Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
Philip Home, Stuart Pocock, Henning Beck‐Nielsen et al. · New England Journal of Medicine · 2007 · 763 citations · Full text
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
James D. Lewis, Assiamira Ferrara, Tiffany Peng et al. · Diabetes Care · 2011 · 621 citations · Full text
Medicine, Oncology, Pharmacology +13
Neprilysin Gene Transfer Reduces Human Amyloid Pathology in Transgenic Mice
Robert A. Marr, Edward Rockenstein, Atish Mukherjee et al. · Journal of Neuroscience · 2003 · 387 citations · Full text